皮膚血管肉腫に対するIL-2を組み込んだ集学的治療―イムネース研究会3年間のまとめ―

Fifty-seven patients with angiosarcoma, who were consecutively registered for three years from 48 institutions, were treated with IL-2 containing maltidisciplinary therapy, and we studied the therapeutic results from a different point of view; sex, age, location of the lesion, duration from the onset, the kind of previous treatment, therapeutic regimen, the way of administration of IL-2, response rate and the survival rate. The survival rate at 30 months follow-up, was at 13.2% in 21 patients treated with combination of IL-2 and irradiation. At 36 months of evaluation of 12 patients after IL-2 and surgical treatment, survival rate was 40%. At 18 months of evaluation of 8 patients treated with IL-2, irradiation and surgical treatment, survival rate was 36.5%. Survival rate of three years of 17 patients who achieved a complete response (CR) was 81.5%. Survival rate of 29 months of 19 patients who received a partial response (PR) was 28%. And all patients who could not achieve CR and PR died until 13 months. The suvival time of the responding patients was significantly better than that of patients with MR, NC and PD, that is, CR group is better than PR group, CR group is better than MR, NC and PD group and PR group is better than MR, NC and PD group, respectively (G.W. p<0.01).